SDGR
What one share of Schrodinger holds
Pharmaceutical Preparations
Our differentiated, physics-based computational platform enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at a lower cost, compared to traditional methods.
Schrodinger’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $3.50 |
|---|---|
| Profit | −$0.73 |
| Capex (buildings and equipment) | $0.05 |
| Free cash flow | −$1.76 |
| Cash and investments | $5.54 |
| Book value | $4.40 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | $14.25 | −$4.09 | $0.31 | −$4.65 | — | −$15.25 |
| 2020 | $1.80 | −$0.41 | $0.04 | $0.24 | — | $10.28 |
| 2021 | $1.95 | −$1.42 | $0.10 | −$1.10 | — | $9.01 |
| 2022 | $2.54 | −$2.10 | $0.11 | −$1.79 | — | $7.21 |
| 2023 | $2.89 | $0.54 | $0.18 | −$2.00 | — | $8.71 |
| 2024 | $2.86 | −$2.58 | $0.10 | −$2.27 | — | $5.80 |
| 2025 | $3.48 | −$1.41 | $0.02 | $0.17 | — | $4.96 |